title: [Efficacy of an intervention to improve treatment compliance in hyperlipidemias].
abstract: OBJECTIVE
  To analyse the efficacy of the intervention through a telephone call about patients' compliance with lipaemia therapy.
  
  
  METHODS
  Controlled, randomised clinical trial.
  
  
  METHODS
  Ten clinics at 6 primary care centres.
  
  
  METHODS
  126 people diagnosed with hypercholesterolaemia according to Spanish Consensus criteria were chosen.
  
  
  METHODS
  Two groups were formed. The control group (CG) of 63 patients, who received the doctor's normal treatment; and the Intervention group (IG) of 63 patients, who received in addition a telephone call at 2 weeks, 2 months and 4 months.
  
  
  METHODS
  Pills were counted and cholesterol, triglycerides, HDL-C and LDL-C determined at the start, and at the third and sixth months. Percentages of patients complying (80%-110%), the mean compliance percentage and the degree of control were compared. The reduction of absolute and relative risk (RAR and RRR) and the mean number of people that required an intervention in order to avoid non-compliance (NI) were calculated.
  
  
  RESULTS
  115 people (91.26%) completed the survey, 56 in the IG and 59 in the CG. 77.1% complied with the therapy (CI, 68.4-85.8), (CG=64.4%, CI, 55.3-73.5; IG=93.5%, CI, 88.8-98 [P<.001]). Mean compliance ran at 88.7 +/- 10.2 overall, at 84.4 +/- 12.8 in the CG and at 93 +/- 8.2 in the IG (P<.001). The RAR was 29.1%, the RRR 81%, and the NI was 3.43 patients. The patients controlled ran at 43.9% in the IG (CI, 34.9-52.9) and 23.1% in the CG (CI, 15.4-30.8) (P<.005).
  
  
  CONCLUSIONS
  The telephone intervention is an efficacious way of improving the percentage of patients complying with lipaemia treatment.
authors.affiliation: Medicina Familiar y Comunitaria, Centro de Salud la Orden, Avda. Italia 107, 5.o A. 21003 Huelva, Spain. emarquezc@papps.org
authors.forename: E
authors.initials: E
authors.lastname: Márquez Contreras
authors.forename: J J
authors.initials: JJ
authors.lastname: Casado Martínez
authors.forename: Y
authors.initials: Y
authors.lastname: Corchado Albalat
authors.forename: R
authors.initials: R
authors.lastname: Chaves González
authors.forename: A
authors.initials: A
authors.lastname: Grandío
authors.forename: C
authors.initials: C
authors.lastname: Losada Velasco
authors.forename: J
authors.initials: J
authors.lastname: Obando
authors.forename: J M
authors.initials: JM
authors.lastname: de Eugenio
authors.forename: J M
authors.initials: JM
authors.lastname: Barrera
mesh_terms: D016022:Case-Control Studies; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D013689:Telephone; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol